CIK 0001622229 · Large accelerated filer
Cogent Biosciences, Inc.
Sign in to watch- Ticker
- COGT
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 465308248
- Phone
- 617-945-5576
- Business address
- 180 THIRD AVENUE, 4TH FLOOR, WALTHAM, MA
- Former names
- Unum Therapeutics Inc., Unum Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,689,493
- in 1 filing, $1.7M under 10b5-1 plans
Net −$1,689,493. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-03-28 | Fairmount Funds Management LLC Director | Other disposition | −286,851 | 0 | ||
| 2024-03-28 | Fairmount Funds Management LLC Director | Other acquisition | +286,851 | 4,725,641 | ||
| 2024-03-28 | Fairmount Funds Management LLC Director | Other disposition · Series A Convertible Preferred Stock | −11,914 | 0 | ||
| 2024-03-28 | Fairmount Funds Management LLC Director | Other acquisition · Series A Convertible Preferred Stock | +11,914 | 67,414 | ||
| 2024-02-16 | Fairmount Funds Management LLC 10% owner | Grant or award | +1,166,666 | $7.50 | $8.7M | 4,438,790 |
| 2024-02-16 | Fairmount Funds Management LLC 10% owner | Grant or award · Series B Convertible Preferred Stock | +1,500 | $7,500.00 | $11.3M | 1,500 |
| 2024-01-23 | Robinson John Edward Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +300,000 | 300,000 | ||
| 2024-01-23 | Kearns Evan Chief Legal Officer | Grant or award · Stock Option (Right to Buy) | +255,000 | 255,000 | ||
| 2024-01-23 | Sachs Jessica Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +300,000 | 300,000 | ||
| 2024-01-23 | Robbins Andrew R President and CEO | Grant or award · Stock Option (Right to Buy) | +1,100,000 | 1,100,000 | ||
| 2024-01-23 | Green John L. Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +300,000 | 300,000 | ||
| 2024-01-02 | Ferrante Karen Jean Director | Grant or award · Stock Option (Right to Buy) | +3,298 | 3,298 | ||
| 2024-01-02 | Ros Matthew Director | Grant or award · Stock Option (Right to Buy) | +3,051 | 3,051 | ||
| 2023-10-02 | Ros Matthew Director | Grant or award · Stock Option (Right to Buy) | +2,170 | 2,170 | ||
| 2023-10-02 | Ferrante Karen Jean Director | Grant or award · Stock Option (Right to Buy) | +2,345 | 2,345 | ||
| 2023-07-03 | Ferrante Karen Jean Director | Grant or award · Stock Option (Right to Buy) | +1,884 | 1,884 | ||
| 2023-07-03 | Ros Matthew Director | Grant or award · Stock Option (Right to Buy) | +1,743 | 1,743 | ||
| 2023-06-09 | Fairmount Funds Management LLC 10% owner | Purchase | +800,000 | $12.00 | $9.6M | 3,272,124 |
| 2023-06-07 | Morris Arlene Director | Grant or award · Stock Option (Right to Buy) | +36,700 | 36,700 | ||
| 2023-06-07 | CAIN CHRISTOPHER W. Director | Grant or award · Stock Option (Right to Buy) | +36,700 | 36,700 |
Page 5 of 7 · 131 trades